JP2024521987A - ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法 - Google Patents

ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法 Download PDF

Info

Publication number
JP2024521987A
JP2024521987A JP2023568539A JP2023568539A JP2024521987A JP 2024521987 A JP2024521987 A JP 2024521987A JP 2023568539 A JP2023568539 A JP 2023568539A JP 2023568539 A JP2023568539 A JP 2023568539A JP 2024521987 A JP2024521987 A JP 2024521987A
Authority
JP
Japan
Prior art keywords
amino acids
knob
region
sequence
ultralong cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521987A5 (enExample
Inventor
マクレガー，ダンカン
ホアン，ルイチー
ジェンキンス，ガブリエル ワーナー
スマイダー，ボーン
Original Assignee
アプライド バイオメディカル サイエンス インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプライド バイオメディカル サイエンス インスティチュート filed Critical アプライド バイオメディカル サイエンス インスティチュート
Publication of JP2024521987A publication Critical patent/JP2024521987A/ja
Publication of JP2024521987A5 publication Critical patent/JP2024521987A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pulmonology (AREA)
JP2023568539A 2021-05-12 2022-05-11 ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法 Pending JP2024521987A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163187931P 2021-05-12 2021-05-12
US63/187,931 2021-05-12
US202163288992P 2021-12-13 2021-12-13
US63/288,992 2021-12-13
PCT/US2022/028864 WO2022241058A1 (en) 2021-05-12 2022-05-11 Methods of screening and expression of disulfide-bonded binding polypeptides

Publications (2)

Publication Number Publication Date
JP2024521987A true JP2024521987A (ja) 2024-06-05
JP2024521987A5 JP2024521987A5 (enExample) 2025-05-19

Family

ID=82321343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568539A Pending JP2024521987A (ja) 2021-05-12 2022-05-11 ジスルフィド結合した結合ポリペプチドのスクリーニング及び発現の方法

Country Status (8)

Country Link
US (1) US20240218052A1 (enExample)
EP (1) EP4337690A1 (enExample)
JP (1) JP2024521987A (enExample)
KR (1) KR20240007256A (enExample)
AU (1) AU2022272307A1 (enExample)
CA (1) CA3218571A1 (enExample)
IL (1) IL308087A (enExample)
WO (1) WO2022241058A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023379740A1 (en) * 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
US20260201020A1 (en) * 2022-12-05 2026-07-16 Pelican Technology Holdings, Inc. Methods for expression of fusion-free bovine ultralong cdr3 scaffold

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504896A (ja) * 2012-01-09 2015-02-16 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
WO2021191424A1 (en) * 2020-03-27 2021-09-30 UCB Biopharma SRL Autonomous knob domain peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP2555798B1 (en) 2010-04-09 2016-06-22 Reef Pharmaceuticals Pty Ltd Methods and compositions for inhibiting hiv transmission
EP2802601B1 (en) * 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2015017146A2 (en) * 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) * 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
CN112566650A (zh) 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504896A (ja) * 2012-01-09 2015-02-16 ザ・スクリップス・リサーチ・インスティテュート 超長相補性決定領域及びその使用
WO2021191424A1 (en) * 2020-03-27 2021-09-30 UCB Biopharma SRL Autonomous knob domain peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEX MACPHERSON ET AL.: ""Isolation of antigen-specific, disulphide-rich knob domain peptides from bovine antibodies"", PLOS BIOLOGY, vol. 18, no. 9, JPN6026008699, 4 September 2020 (2020-09-04), pages 3000821 - 1, ISSN: 0005813234 *

Also Published As

Publication number Publication date
AU2022272307A1 (en) 2023-11-16
WO2022241058A1 (en) 2022-11-17
US20240218052A1 (en) 2024-07-04
EP4337690A1 (en) 2024-03-20
CA3218571A1 (en) 2022-11-17
KR20240007256A (ko) 2024-01-16
IL308087A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7324789B2 (ja) ヒト化抗ｍｕｃ１＊ 抗体
TWI671318B (zh) 介白素－２融合蛋白及其用途
CN108473987B (zh) 具有改变的多样性支架结构域的结合成员
KR102271204B1 (ko) 다중특이적 항체 작제물
JP7089806B2 (ja) 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
US7718174B2 (en) Anti-HGF/SF humanized antibody
JP2021519610A (ja) 多価抗体
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
MX2015001749A (es) Proteinas de fusion de interleuquina-2 y usos de las mismas.
EP2668206A1 (en) Engineering of immunoglobulin domains
KR20220160069A (ko) 자율적 노브 도메인 펩티드
EP4277925A1 (en) Multi-specific antibodies and methods of use
US20240262893A1 (en) Binding polypeptides against sars cov-2 and uses thereof
US20240218052A1 (en) Methods of screening and expression of disulfide-bonded binding polypeptides
CN111742220A (zh) 检测癌症患者中的肿瘤抗原的诊断性测定法
CN113698492B (zh) 人间皮素嵌合抗原受体及其用途
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
AU2023379740A1 (en) Fusion polypeptides and binding peptides and methods for producing and using same
CN117545768A (zh) 二硫键结合的结合多肽的筛选和表达的方法
JP2023526477A (ja) 合成単一ドメインライブラリー
US20250312453A1 (en) Antibody targeting ccr8 and its applications
CN121712801A (zh) 包含空间位阻部分的CyCAT半体分子
HK40093102A (en) Humanized anti-muc1* antibodies
CN115521380A (zh) 靶向gpc3的抗原结合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260810